Top Page
China Medical System Holdings
(OTC:0867)
China Medical System Holdings (0867) vs. iShares MSCI Hong Kong ETF (EWH)
China Medical System Holdings Business Overview & Revenue Model
China Medical System Holdings Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.47B | 8.01B | 9.15B | 8.34B | 6.95B |
| Gross Profit | 5.42B | 6.11B | 7.04B | 6.25B | 5.13B |
| EBITDA | 2.31B | 2.92B | 3.85B | 3.70B | 3.05B |
| Net Income | 1.62B | 2.40B | 3.26B | 3.02B | 2.53B |
Balance Sheet | |||||
| Total Assets | 18.05B | 17.73B | 17.75B | 15.81B | 12.70B |
| Cash, Cash Equivalents and Short-Term Investments | 5.87B | 6.14B | 5.87B | 4.36B | 2.67B |
| Total Debt | 860.74M | 1.30B | 1.81B | 1.71B | 600.16M |
| Total Liabilities | 1.64B | 2.17B | 3.02B | 2.96B | 1.60B |
| Stockholders Equity | 16.31B | 15.52B | 14.59B | 12.75B | 11.03B |
Cash Flow | |||||
| Free Cash Flow | 812.64M | 2.18B | 3.03B | 2.31B | 2.35B |
| Operating Cash Flow | 1.27B | 2.50B | 3.55B | 2.49B | 2.69B |
| Investing Cash Flow | -615.10M | -442.28M | -1.18B | -1.52B | -353.82M |
| Financing Cash Flow | -1.26B | -2.13B | -1.40B | -258.39M | -1.03B |
China Medical System Holdings Technical Analysis
China Medical System Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $32.45B | 18.38 | 10.17% | 0.62% | -8.91% | -34.40% | |
65 Neutral | ¥355.44B | 11.35 | -2.99% | 2.49% | 11.76% | -10.21% | |
| ― | $3.76B | 9.10 | 19.62% | 1.98% | ― | ― | |
| ― | $5.86B | 10.40 | 7.22% | 2.17% | ― | ― | |
| ― | $5.13B | 13.13 | 14.56% | 1.25% | ― | ― | |
| ― | €3.85B | 8.61 | 4.91% | ― | ― | ||
78 Outperform | HK$33.54B | 13.41 | 15.61% | 2.84% | 10.59% | 31.83% |
China Medical System Holdings Corporate Events
China Medical System Holdings Limited has successfully achieved a secondary listing on the Singapore Exchange’s Main Board, with its shares now traded under the stock code ‘8A8’. This strategic move is expected to enhance the company’s market presence and accessibility for investors in Singapore, while maintaining its primary listing on the Hong Kong Stock Exchange.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited announced that its innovative drug CMS-D001, a highly selective TYK2 inhibitor, has received approval from the National Medical Products Administration of China to conduct clinical trials for atopic dermatitis. This approval marks an expansion of CMS-D001’s indications, which already include psoriasis, and highlights the company’s commitment to addressing unmet needs in dermatological treatments. The drug is expected to offer reliable efficacy and safety, enhancing the company’s portfolio in skin health and potentially improving the quality of life for patients with skin diseases.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited announced its expected secondary listing on the Singapore Exchange, with trading set to commence on July 15, 2025. This move is part of the company’s strategic efforts to expand its market reach and enhance its financial flexibility, although the completion of the listing is contingent upon meeting certain conditions.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced the receipt of an eligibility-to-list letter from the Singapore Exchange Securities Trading Limited for a proposed secondary listing of its ordinary shares. This move, which does not involve the issuance of new shares, aims to expand the company’s market presence and trading opportunities, although it remains subject to certain conditions and regulatory compliance.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$12.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced its intention to pursue a secondary listing of its issued ordinary shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This strategic move is expected to enhance the company’s market presence and provide additional opportunities for investment, potentially impacting its operations and positioning within the industry.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$12.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced its intention to pursue a secondary listing of its ordinary shares on the Singapore Exchange Securities Trading Limited. This strategic move is aimed at enhancing the company’s presence in the Singapore market, increasing its global visibility, and facilitating international business expansion. Although the listing will not involve issuing new shares, it is expected to broaden the shareholder base and open additional fundraising channels in the future, thereby improving the company’s corporate image and liquidity of its securities.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.